A Look At Glaukos (GKOS) Valuation As Epioxa Showcased At ASCRS Annual Meeting
Glaukos (GKOS) is gaining investor attention as it features its Epioxa corneal cross-linking treatment at the ASCRS annual meeting. The stock is currently trading at a discount to both analyst price targets and an intrinsic value model, with recent strong share price performance. The company's diversified pipeline in corneal health, glaucoma devices, and retinal programs is expected to drive future growth despite execution and reimbursement risks.
Glaukos Stock 5-Day Winning Spree: Stock Climbs 13%
Glaukos (GKOS) stock achieved a 5-day winning streak, increasing its value by 13% and boosting its market capitalization by $777 million to $6.7 billion. Despite this recent surge, the stock is considered "Unattractive" due to its "Very High valuation" and only "Moderate operating performance and financial condition." The article suggests that while the winning streak is notable, the market has already factored in this news, emphasizing the need for predictive signals for future gains.
Glaukos to Present Multiple Scientific Abstracts at ASCRS Annual Meeting
Glaukos Corporation will present multiple scientific abstracts at the 2026 ASCRS Annual Meeting, focusing on its new FDA-approved corneal cross-linking treatment, Epioxa. This innovative therapy is described as the first and only epithelium-on, oxygen-enriched treatment of its kind, offering a less invasive alternative to traditional procedures. The presentation highlights Glaukos' commitment to advancing corneal health and bringing new solutions to eye care professionals and patients.
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation will present multiple scientific abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. The presentations will highlight advancements in glaucoma and corneal health, including 12-month outcomes of micro-bypass stents and the Travoprost Intracameral Implant, as well as real-world outcomes of combined treatments. Glaukos is also sponsoring an educational symposium on its FDA-approved epithelium-on corneal cross-linking treatment, Epioxa™.
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation announced its participation in the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, where its technologies will be featured in various scientific programs. The company will also sponsor an educational symposium introducing Epioxa™, the first FDA-approved, epithelium-on, oxygen-enriched corneal cross-linking treatment. Multiple presentations will cover advancements in glaucoma and corneal health, including 12-month outcomes of trabecular micro-bypass stents and Travoprost Intracameral Implant.
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS
Capricorn Fund Managers Ltd has acquired a new stake of 60,000 shares, valued at $6.78 million, in Glaukos Corporation (NYSE:GKOS) during Q4, making Glaukos its 23rd largest position. Despite Glaukos beating revenue estimates but missing on EPS, analysts maintain a "Moderate Buy" rating with a mean price target of $133.69. However, company insiders have been net sellers, offloading 324,657 shares worth approximately $37.7 million over the past three months.
Glaukos (GKOS) CEO gifts 180,308 shares to family trust
Glaukos CEO Thomas William Burns reported a non-market transaction where he gifted 180,308 shares of common stock from his direct ownership to the Burns Family Trust. Additionally, 9,937 shares were withheld by Glaukos at $109.60 per share to cover tax obligations from vested restricted stock units. Following these transactions, Burns continues to hold Glaukos common stock directly and indirectly through various trusts.
Glaukos (GKOS) president uses 3,169 shares to cover tax withholding
Glaukos president and COO Joseph E. Gilliam reported a routine tax-withholding disposition of 3,169 shares of common stock at $109.60 per share. This was done to cover tax obligations arising from the vesting of previously granted restricted stock units. After this non-market transaction, Gilliam directly holds 92,992 shares, including unvested restricted stock units.
Glaukos (NYSE: GKOS) CFO withholds 1,589 shares for RSU tax obligations
Glaukos Corp's CFO, Alex R. Thurman, reported a routine tax-related disposition where 1,589 shares of common stock were withheld by the company to cover his tax obligations upon the vesting of restricted stock units. After this transaction, Thurman directly holds 43,681 shares, with an additional 5,230 unvested restricted stock units still outstanding. The transaction, dated April 2, 2026, was not an open-market sale but an F-code transaction for tax purposes.
GLAUKOS (GKOS) CDO has 5,798 shares withheld to cover RSU tax
GLAUKOS Corp's Chief Development Officer, Tomas Navratil, had 5,798 shares withheld by the company on March 31, 2026, at $109.60 per share to cover tax obligations from vested Restricted Stock Units (RSUs). Following this transaction, Navratil directly holds 95,440 shares, which includes 45,793 unvested RSUs. This disposition is a routine tax-withholding event and not an open-market sale, as indicated by transaction code 'F'.
Cash per share of Glaukos Corp – DUS:6GJ
This page from TradingView provides financial information for Glaukos Corp (DUS:6GJ), specifically focusing on its cash per share. It indicates that the market is currently closed for this stock on the Dusseldorf Stock Exchange. The page also offers sections for overview, financials, news, community, forecasts, seasonals, bonds, and ETFs related to Glaukos Corp.
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC increased its stake in Glaukos Corporation (NYSE:GKOS) by 32.8% in the fourth quarter, now owning 355,279 shares valued at $39.3 million. Institutional investors now hold approximately 99.04% of the shares, while company insiders sold about 324,657 shares worth $37.7 million during the quarter. Glaukos has a consensus "Moderate Buy" rating from analysts with an average price target of $133.69, and reported revenues beating expectations but an EPS miss in its last earnings call.
GKOS PE Ratio & Valuation, Is GKOS Overvalued
Glaukos Corp (GKOS) is currently considered to be in the "Fair zone" according to its valuation metrics, with a forward PS ratio of 7.98. Its fair price is estimated to be between $101.11 and $173.90 using a relative valuation method. While its P/S ratio is above the industry average, this premium is deemed sustainable due to robust revenue growth.
SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS
SG Americas Securities LLC significantly increased its holdings in Glaukos Corporation (NYSE:GKOS) by purchasing 49,492 shares in Q4, bringing its total to 60,232 shares valued at approximately $6.8 million. This surge in institutional ownership (now 99.04%) contrasts with substantial insider selling, where CEO Thomas Burns and other insiders sold shares worth over $37 million. Despite missing Q4 EPS estimates, Glaukos reported strong revenue growth, with analysts maintaining a "Moderate Buy" rating and an average price target of $133.69.
Price-Driven Insight from (GKOS) for Rule-Based Strategy
This article provides a price-driven analysis for Glaukos Corporation (NASDAQ: GKOS), highlighting a strong sentiment that could lead to long-term positive bias. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points. The analysis also includes multi-timeframe signal strengths and support/resistance levels for near, mid, and long-term horizons, advising on current positioning based on prevailing positive sentiment.
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility
Glaukos Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has seen its stock price adjust amid market fluctuations. Despite recent short-term challenges, the company has delivered impressive long-term returns, significantly surpassing the S&P 500, with a remarkable 544.47% return over the past decade. The stock currently trades at $103.18, reflecting mixed technical indicators and volatility within a 52-week high of $129.96 and a low of $73.16.
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock
Glaukos Corporation's CFO, Alex Thurman, sold 2,511 shares of company stock for $267,321.06 on March 25th, reducing his holding by 5.65%. The medical instruments supplier recently reported a Q4 revenue of $143.12 million, exceeding estimates, but missed EPS forecasts with a ($0.28) loss. Analysts currently rate Glaukos as a "Moderate Buy" with an average target price of $133.69, and institutional investors own approximately 99.04% of the stock.
Glaukos (NYSE: GKOS) president reports new stock and option grants
Joseph E. Gilliam, President & COO of Glaukos (NYSE: GKOS), received new stock and option grants on March 25, 2026, as reported in a Form 4 filing. These compensation-related awards include stock options for 16,462, 21,955, and 36,751 shares, with varying exercise prices, and restricted stock unit-based awards for 5,829 and 17,792 shares. The grants are tied to the company's achievement of multi-year operational and performance targets, with specific vesting schedules in 2026 and over four years annually.
Glaukos (GKOS) CEO gains RSUs and options after targets met
Glaukos Corp's Chairman and CEO, Thomas William Burns, was awarded significant equity compensation including stock options and restricted stock units. These awards were granted or earned following the company's achievement of specific operational targets, determined by the board on March 25, 2026. The new grants reflect both performance-based vesting from prior awards and a new option grant that vests over four years, substantially increasing his direct and indirect holdings in the company.
GLAUKOS (GKOS) CDO Tomas Navratil earns performance RSU stock awards
GLAUKOS Chief Development Officer Tomas Navratil was awarded performance-based stock grants of common shares on March 25, 2026. These restricted stock units (RSUs) were earned because the company's Compensation, Nominating and Governance Committee determined that specific multi-year operational performance targets from RSU grants issued in 2022, 2023, and 2024 had been successfully achieved. Following these awards, Navratil now directly holds 101,238 common shares and still possesses additional unvested RSUs, including 57,486 units not yet delivered.
Glaukos (NYSE: GKOS) CFO gets new equity awards and sells shares
Glaukos Corp (NYSE: GKOS) CFO Alex R. Thurman reported selling 2,511 shares of common stock at $106.46 per share under a pre-arranged Rule 10b5-1 trading plan. Concurrently, he received significant new equity awards, including stock options for 8,228 shares at $55.18 and 20,515 shares at $109.60, along with 3,303 shares from a performance-based restricted stock unit award due to achieved operational targets. Despite the sale, Thurman's direct ownership, including unvested units, now stands at 45,270 shares, indicating a substantial ongoing equity stake in the company.
Glaukos SVP Thurman sells $267k in GKOS stock
Glaukos Senior Vice President and CFO Alex R. Thurman sold 2,511 shares of GKOS stock for over $267,000 as part of a pre-arranged trading plan, while also acquiring additional shares and stock options. Despite the company's current unprofitability, analysts have reiterated positive ratings and price targets, following the FDA's approval for re-administration of its iDose TR and expected product momentum.
Glaukos Corporation (NYSE:GKOS): Is Breakeven Near?
This article analyzes whether Glaukos Corporation (NYSE:GKOS) is approaching profitability. It will likely examine the company's financials, growth trajectory, and market position to assess its path to breaking even. Investors interested in GKOS would find this assessment valuable.
Riverbridge Partners LLC Sells 34,475 Shares of Glaukos Corporation $GKOS
Riverbridge Partners LLC reduced its stake in Glaukos Corporation (NYSE:GKOS) by 6.1% in the fourth quarter, selling 34,475 shares and bringing its total holdings to 535,169 shares. Despite this reduction, Glaukos remains a significant holding for Riverbridge, representing 1.1% of its portfolio. Corporate insiders have also been selling shares, with a total of 322,146 shares sold in the last 90 days, though insiders still own 5.8% of the company.
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For Keratoconus - What's Changed
Glaukos Corporation (GKOS) has seen a 5.5% stock increase following the launch of Epioxa, an incision-free corneal cross-linking therapy for keratoconus. This new therapy, combined with expanded patient access programs, aims to address the underdiagnosis and undertreatment of the eye disease. The launch integrates into Glaukos' strategy of broadening its interventional ophthalmology platform, though it also introduces risks related to payer adoption and the transition from existing products.
Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS
Assenagon Asset Management S.A. significantly increased its stake in Glaukos Corporation (NYSE:GKOS) by 15.8%, holding 182,393 shares valued at $20.59 million. This increase comes despite recent insider selling by Glaukos's CFO and COO, totaling $37.42 million in sales over the last 90 days. Glaukos reported a revenue increase of 35.6% year-over-year but missed EPS estimates, yet analysts maintain a "Moderate Buy" rating with an average target price of $133.69.
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For Keratoconus - What's Changed
Glaukos Corporation launched Epioxa, an incision-free therapy for keratoconus, aiming to address underdiagnosis and undertreatment of the disease. This move, along with a recent FDA approval for iDose TR, expands Glaukos' reach in ophthalmology but also increases exposure to reimbursement decisions and physician training challenges. The company's investment narrative projects significant revenue and earnings growth by 2028, with varying analyst optimism.
Vanguard realigns reporting; Vanguard subsidiaries to report GKOS holdings (GKOS)
The Vanguard Group has filed an amended Schedule 13G/A for Glaukos Corp (GKOS), reporting 0 shares beneficially owned. This change is due to an internal realignment, where Vanguard's subsidiaries will now report beneficial ownership separately on a "disaggregated basis" in accordance with SEC Release No. 34-39538. The amendment clarifies that this is a reclassification of reporting responsibility rather than a sale of GKOS shares by Vanguard.
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 1,521 Shares of Stock
Glaukos (NYSE:GKOS) CFO Alex Thurman sold 1,521 shares of the company's stock for over $160,000, reducing his stake by 3.17%. This insider sale occurred as the company reported a Q1 EPS miss but a revenue beat, with the stock trading near $109.48 and analysts maintaining a "Moderate Buy" rating. The article also details institutional investment changes and recent analyst target price adjustments for Glaukos.
Glaukos (GKOS) CEO uses 2,744 shares to cover equity tax withholding
Glaukos Corp's Chairman and CEO, Thomas William Burns, reported a tax-withholding share disposition. On March 24, 2026, 2,744 shares of common stock were withheld by the company at $105.23 per share to cover tax obligations upon the vesting of previously granted restricted stock units. Following this non-market transaction, Burns directly holds 239,707 common shares and also has indirect ownership through several family trusts, with 59,399 restricted stock units remaining unvested.
Glaukos (NYSE: GKOS) CDO has shares withheld to cover tax obligations
Glaukos Corp's Chief Development Officer, Tomas Navratil, reported tax-related share withholdings from restricted stock unit vesting. A total of 5,174 shares were withheld on March 23 and 24, 2026, at prices of $106.84 and $105.23 respectively, to cover tax obligations. These were not open-market sales but routine transactions to satisfy tax liabilities on vested RSUs, with Navratil retaining 68,457 direct shares and additional unvested RSUs.
Glaukos (GKOS) president sees 15,118 shares withheld to cover tax obligations
Glaukos Corp's president and COO, Joseph E. Gilliam, reported the withholding of 15,118 shares of common stock to cover tax obligations arising from restricted stock unit vesting on March 23 and 24, 2026. These were routine dispositions for tax purposes, not open-market sales. Following these transactions, Gilliam directly holds 72,540 shares, with additional unvested restricted stock units.
Glaukos (NYSE: GKOS) insider plans sale of 2,511 vested shares
An insider at Glaukos (NYSE: GKOS) has filed a Form 144 notice to sell 2,511 shares of common stock. These shares are tied to a restricted stock vesting event that occurred on March 24, 2026, and are classified as compensation. The filing also reports previous sales of 625 shares on March 17, 2026, and 1,521 shares on March 24, 2026.
Glaukos (GKOS) affiliate files to sell 1,521 shares after vesting
Glaukos Corp. (GKOS) has filed a Form 144 indicating a proposed sale of 1,521 shares of Common Stock following a restricted stock vesting on March 22, 2026. The filing also notes a prior sale of 625 shares by Alex Thurman on March 17, 2026, for $61,968.75. Fidelity Brokerage Services LLC is identified as the broker for these compensation-related transactions.
Piper Sandler reiterates Glaukos stock rating on growth outlook
Piper Sandler reiterated an Overweight rating and a $165.00 price target for Glaukos Corporation (NYSE: GKOS), citing the company's strong growth outlook and multiple pathways to meet future revenue estimates. Management anticipates significant growth through its iDose and Epioxa products, with preparations for the next phase of iDose in late 2026 and positive initial results for Epioxa. Other analysts, including BTIG, Needham, and Stifel, have also issued positive ratings and increased price targets following the FDA approval for iDose TR re-administration.
Piper Sandler reiterates Glaukos stock rating on growth outlook
Piper Sandler has reiterated an Overweight rating and $165.00 price target for Glaukos Corporation (NYSE:GKOS), citing multiple avenues for the company to achieve its fiscal 2026 iDose revenue estimates. Management expressed confidence in future growth, including the next phase of iDose and positive initial results for Epioxa, which analysts believe is an underappreciated asset. This positive outlook is further supported by recent FDA approval for iDose TR re-administration and several other firms maintaining their Buy ratings with increased price targets.
Why is Glaukos (GKOS) down 14.7% since last earnings report?
This article from Zacks Equity Research focuses on Glaukos (GKOS) and its stock performance since its last earnings report, noting a 14.7% decline. It provides an overview of the company's financial health, including key metrics like price-to-earnings ratios, sales, and past earnings surprises. The piece also briefly touches on Glaukos' business in ophthalmology, specifically mentioning its iStent technology for glaucoma and corneal health products.
JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS
JPMorgan Chase & Co. increased its stake in Glaukos Corporation (NYSE:GKOS) by 4.3% in the third quarter, bringing its total holding to 670,083 shares valued at $54.65 million. Despite institutional buying, Glaukos's insiders have been net sellers, with the CEO and other insiders selling significant amounts of stock. The company recently reported a revenue increase of 35.6% year-over-year but missed EPS estimates, while analysts maintain a "Moderate Buy" rating with an average target price of $133.69.
Glaukos Introduces Epioxa, Accelerating Expansion in Corneal Therapy
Glaukos Corporation has launched Epioxa, an FDA-cleared, non-surgical topical medication for keratoconus, which aims to expand the treatment market by offering a less invasive alternative to traditional corneal cross-linking. Despite a recent stock dip, Glaukos expects Epioxa to drive significant growth by increasing diagnosis rates and patient access for the largely untapped keratoconus population. The company is actively investing in awareness, screening, and patient support to fully leverage this new therapy's potential in a growing global market.
Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care
Glaukos Corporation has announced the commercial availability of Epioxa HD/Epioxa, an FDA-approved topical drug therapy for keratoconus that does not require the removal of the corneal epithelium. This incision-free treatment aims to improve patient comfort and minimize recovery time, offering a new standard of care for keratoconus patients. Glaukos plans to increase investments in patient awareness, education, and access to address underdiagnosis and undertreatment of the condition.
Navratil, Glaukos corp officer, sells $101k in GKOS stock
Tomas Navratil, Chief Development Officer at Glaukos Corp (NASDAQ:GKOS), sold 1,031 shares of company stock worth approximately $101,078 and had 958 shares withheld for tax obligations. This comes amidst recent FDA approval for Glaukos' iDose TR product and analysts like BTIG, Needham, and Stifel maintaining Buy ratings and increasing price targets for the company. Despite the insider sale, Glaukos' stock trades at $102.09 with a market capitalization of $5.92 billion.
Navratil, Glaukos corp officer, sells $101k in GKOS stock
Tomas Navratil, Chief Development Officer at Glaukos Corp (NASDAQ:GKOS), sold 1,031 shares of company stock worth approximately $101,078 on March 16, 2026. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. The company recently received FDA approval for a labeling supplement for its iDose TR product, leading several analysts to raise their price targets and maintain "Buy" ratings on Glaukos stock.
Glaukos Corporation (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages
Sixteen brokerages have given Glaukos Corporation (NYSE:GKOS) an average rating of "Moderate Buy," with an average 12-month target price of $133.69. Despite missing EPS estimates but beating revenue expectations in its latest quarter, several analysts have raised their price targets for the stock. Insider selling has occurred, but institutional investors hold a significant majority of the shares.
Glaukos SVP Thurman sells $61,968 in GKOS stock
Glaukos Senior Vice President and CFO Alex R. Thurman sold 625 shares of GKOS common stock for $61,968 on March 17, 2026, under a Rule 10b5-1 trading plan. Additionally, 614 shares were withheld for tax obligations related to restricted stock units. Despite strong revenue growth, the company remains unprofitable, and InvestingPro analysis suggests the stock is currently overvalued.
Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care
Glaukos Corporation has announced the commercial availability of Epioxa HD/Epioxa, an incision-free topical therapy for keratoconus. This FDA-approved treatment eliminates the need for corneal epithelium removal, aiming to improve patient comfort and reduce recovery time. Glaukos plans to invest significantly in patient awareness, education, and access programs to address underdiagnosis and undertreatment of the condition.
Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 625 Shares
Glaukos CFO Alex Thurman sold 625 shares of the company's stock on March 17th for a total of $61,968.75, reducing his ownership by 1.25%. Despite missing EPS estimates, Glaukos reported a significant 35.6% year-over-year revenue increase. Institutional ownership remains high at 99.04%, and analysts maintain a largely bullish outlook with a consensus target price of $133.69.
[Form 4] GLAUKOS Corp Insider Trading Activity
GLAUKOS Corp Chairman and CEO Thomas William Burns reported a tax-related disposition of 2,801 common shares on March 16, 2026, to cover tax obligations from previously granted restricted stock units. The shares were withheld by the company at $98.94 each. Following this transaction, Burns directly holds 242,451 common shares and has significant indirect holdings through various trusts, with an additional 64,610 unvested restricted stock units.
GLAUKOS (NYSE: GKOS) COO reports tax-withholding of 1,189 vested shares
GLAUKOS Corp's COO, Joseph E. Gilliam, reported the tax-withholding of 1,189 common shares to cover tax obligations upon the vesting of restricted stock units. This is a routine event related to compensation, not an open-market sale. After this transaction, Gilliam directly holds 87,658 GLAUKOS shares, which includes 53,986 unvested restricted stock units.
Glaukos' Epioxa now commercially available in the US
Glaukos Corporation has commercially launched Epioxa, its FDA-approved, minimally-invasive "epi-on" corneal crosslinking (CXL) treatment for keratoconus, in the U.S. This treatment, available as Epioxa HD and Epioxa, is designed to reduce the duration, complexity, and pain of CXL procedures and is indicated for adults and pediatric patients aged 13+. Glaukos has also introduced the EpioxaCareConnect patient access support program to assist patients with access, reimbursement, and financial options.
Glaukos announces commercial availability of Epioxa for the treatment of keratoconus
Glaukos Corporation has announced the commercial availability of Epioxa™ HD / Epioxa™ for the treatment of keratoconus, a rare corneal disease. This FDA-approved topical drug therapy does not require removal of the corneal epithelium, improving patient comfort and minimizing recovery time. Glaukos plans to increase investments in patient awareness, education, and access for Epioxa, which was approved by the FDA in October 2025 based on data from two successful phase 3 trials.
